Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City.
Lancet Rheumatol
; 4(9): e582-e585, 2022 Sep.
Article
in En
| MEDLINE
| ID: mdl-35856060
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Lancet Rheumatol
Year:
2022
Type:
Article
Affiliation country:
United States